Literature DB >> 29468951

Cost-effectiveness thresholds: methods for setting and examples from around the world.

André Soares Santos1, Augusto Afonso Guerra-Junior1,2, Brian Godman3,4, Alec Morton5, Cristina Mariano Ruas1.   

Abstract

INTRODUCTION: Cost-effectiveness thresholds (CETs) are used to judge if an intervention represents sufficient value for money to merit adoption in healthcare systems. The study was motivated by the Brazilian context of HTA, where meetings are being conducted to decide on the definition of a threshold. AREAS COVERED: An electronic search was conducted on Medline (via PubMed), Lilacs (via BVS) and ScienceDirect followed by a complementary search of references of included studies, Google Scholar and conference abstracts. Cost-effectiveness thresholds are usually calculated through three different approaches: the willingness-to-pay, representative of welfare economics; the precedent method, based on the value of an already funded technology; and the opportunity cost method, which links the threshold to the volume of health displaced. An explicit threshold has never been formally adopted in most places. Some countries have defined thresholds, with some flexibility to consider other factors. An implicit threshold could be determined by research of funded cases. EXPERT COMMENTARY: CETs have had an important role as a 'bridging concept' between the world of academic research and the 'real world' of healthcare prioritization. The definition of a cost-effectiveness threshold is paramount for the construction of a transparent and efficient Health Technology Assessment system.

Entities:  

Keywords:  Cost-benefit analysis; cost-effectiveness analysis; economics, medical; economics, pharmaceutical; expert testimony; review; technology assessment, biomedical

Mesh:

Year:  2018        PMID: 29468951     DOI: 10.1080/14737167.2018.1443810

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  8 in total

1.  Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries.

Authors:  Hamraz Mokri; Ingelin Kvamme; Linda de Vries; Matthijs Versteegh; Pieter van Baal
Journal:  Eur J Health Econ       Date:  2022-08-04

2.  Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.

Authors:  D van Poppelen; V Sisodia; R J de Haan; M G W Dijkgraaf; P R Schuurman; G J Geurtsen; A E M Berk; R M A de Bie; J M Dijk
Journal:  BMC Neurol       Date:  2020-01-31       Impact factor: 2.474

3.  Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.

Authors:  Jiaxin Li; Ziqi Jia; Menglu Zhang; Gang Liu; Zeyu Xing; Xin Wang; Xin Huang; Kexin Feng; Jiang Wu; Wenyan Wang; Jie Wang; Jiaqi Liu; Xiang Wang
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

Review 4.  The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review.

Authors:  Joseph Kazibwe; Adrian Gheorghe; David Wilson; Francis Ruiz; Kalipso Chalkidou; Y-Ling Chi
Journal:  Value Health       Date:  2021-10-29       Impact factor: 5.725

5.  Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan.

Authors:  Imad Treish; Abeer Al Rabayah; Saad Jaddoua; Haitham Tuffaha
Journal:  Pharmacoecon Open       Date:  2021-11-13

6.  Expectations for the Development of Health Technology Assessment in Brazil.

Authors:  Julia Simões Corrêa Galendi; Carlos Antonio Caramori; Clarissa Lemmen; Dirk Müller; Stephanie Stock
Journal:  Int J Environ Res Public Health       Date:  2021-11-13       Impact factor: 3.390

Review 7.  Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Authors:  Chris Sampson; Bernarda Zamora; Sam Watson; John Cairns; Kalipso Chalkidou; Patricia Cubi-Molla; Nancy Devlin; Borja García-Lorenzo; Dyfrig A Hughes; Ashley A Leech; Adrian Towse
Journal:  Appl Health Econ Health Policy       Date:  2022-06-07       Impact factor: 3.686

8.  Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?

Authors:  Sándor Kovács; Bertalan Németh; Dalma Erdősi; Valentin Brodszky; Imre Boncz; Zoltán Kaló; Antal Zemplényi
Journal:  Appl Health Econ Health Policy       Date:  2022-01-18       Impact factor: 3.686

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.